218 related articles for article (PubMed ID: 36964277)
1. Characterization of purinergic signaling in tumor-infiltrating lymphocytes from lower- and high-grade gliomas.
Scholl JN; Weber AF; Dias CK; Lima VP; Grun LK; Zambonin D; Anzolin E; Dos Santos Dias WW; Kus WP; Barbé-Tuana F; Battastini AMO; Worm PV; Figueiró F
Purinergic Signal; 2024 Feb; 20(1):47-64. PubMed ID: 36964277
[TBL] [Abstract][Full Text] [Related]
2. Correlation of immune phenotype with IDH mutation in diffuse glioma.
Berghoff AS; Kiesel B; Widhalm G; Wilhelm D; Rajky O; Kurscheid S; Kresl P; Wöhrer A; Marosi C; Hegi ME; Preusser M
Neuro Oncol; 2017 Oct; 19(11):1460-1468. PubMed ID: 28531337
[TBL] [Abstract][Full Text] [Related]
3. DNA copy number analysis of Grade II-III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status.
Cohen A; Sato M; Aldape K; Mason CC; Alfaro-Munoz K; Heathcock L; South ST; Abegglen LM; Schiffman JD; Colman H
Acta Neuropathol Commun; 2015 Jun; 3():34. PubMed ID: 26091668
[TBL] [Abstract][Full Text] [Related]
4. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
[TBL] [Abstract][Full Text] [Related]
5. Immune cell gene expression signatures in diffuse glioma are associated with IDH mutation status, patient outcome and malignant cell state, and highlight the importance of specific cell subsets in glioma biology.
Mehani B; Asanigari S; Chung HJ; Dazelle K; Singh A; Hannenhalli S; Aldape K
Acta Neuropathol Commun; 2022 Feb; 10(1):19. PubMed ID: 35144680
[TBL] [Abstract][Full Text] [Related]
6. Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomas.
Yang P; Cai J; Yan W; Zhang W; Wang Y; Chen B; Li G; Li S; Wu C; Yao K; Li W; Peng X; You Y; Chen L; Jiang C; Qiu X; Jiang T;
Neuro Oncol; 2016 Aug; 18(8):1099-108. PubMed ID: 26957363
[TBL] [Abstract][Full Text] [Related]
7. Isocitrate dehydrogenase 1-mutated human gliomas depend on lactate and glutamate to alleviate metabolic stress.
Lenting K; Khurshed M; Peeters TH; van den Heuvel CNAM; van Lith SAM; de Bitter T; Hendriks W; Span PN; Molenaar RJ; Botman D; Verrijp K; Heerschap A; Ter Laan M; Kusters B; van Ewijk A; Huynen MA; van Noorden CJF; Leenders WPJ
FASEB J; 2019 Jan; 33(1):557-571. PubMed ID: 30001166
[TBL] [Abstract][Full Text] [Related]
8. Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas.
Kohanbash G; Carrera DA; Shrivastav S; Ahn BJ; Jahan N; Mazor T; Chheda ZS; Downey KM; Watchmaker PB; Beppler C; Warta R; Amankulor NA; Herold-Mende C; Costello JF; Okada H
J Clin Invest; 2017 Apr; 127(4):1425-1437. PubMed ID: 28319047
[TBL] [Abstract][Full Text] [Related]
9. TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups-A meta-analysis of aggregate data.
Vuong HG; Altibi AMA; Duong UNP; Ngo HTT; Pham TQ; Chan AK; Park CK; Fung KM; Hassell L
Crit Rev Oncol Hematol; 2017 Dec; 120():1-9. PubMed ID: 29198322
[TBL] [Abstract][Full Text] [Related]
10. Dysfunctional dendritic cells limit antigen-specific T cell response in glioma.
Friedrich M; Hahn M; Michel J; Sankowski R; Kilian M; Kehl N; Günter M; Bunse T; Pusch S; von Deimling A; Wick W; Autenrieth SE; Prinz M; Platten M; Bunse L
Neuro Oncol; 2023 Feb; 25(2):263-276. PubMed ID: 35609569
[TBL] [Abstract][Full Text] [Related]
11. Characterization of systemic immunosuppression by IDH mutant glioma small extracellular vesicles.
Ludwig N; Rao A; Sandlesh P; Yerneni SS; Swain AD; Bullock KM; Hansen KM; Zhang X; Jaman E; Allen J; Krueger K; Hong CS; Banks WA; Whiteside TL; Amankulor NM
Neuro Oncol; 2022 Feb; 24(2):197-209. PubMed ID: 34254643
[TBL] [Abstract][Full Text] [Related]
12. The presence of TIM-3 positive cells in WHO grade III and IV astrocytic gliomas correlates with isocitrate dehydrogenase mutation status.
Sørensen MD; Nielsen O; Reifenberger G; Kristensen BW
Brain Pathol; 2021 May; 31(3):e12921. PubMed ID: 33244787
[TBL] [Abstract][Full Text] [Related]
13. Intraoperative assessment of isocitrate dehydrogenase mutation status in human gliomas using desorption electrospray ionization-mass spectrometry.
Alfaro CM; Pirro V; Keating MF; Hattab EM; Cooks RG; Cohen-Gadol AA
J Neurosurg; 2019 Jan; 132(1):180-187. PubMed ID: 30611146
[TBL] [Abstract][Full Text] [Related]
14. Impending Impact of Molecular Pathology on Classifying Adult Diffuse Gliomas.
Macaulay RJ
Cancer Control; 2015 Apr; 22(2):200-5. PubMed ID: 26068765
[TBL] [Abstract][Full Text] [Related]
15. New insights into the Immune TME of adult-type diffuse gliomas.
Richard Q; Laurenge A; Mallat M; Sanson M; Castro-Vega LJ
Curr Opin Neurol; 2022 Dec; 35(6):794-802. PubMed ID: 36226710
[TBL] [Abstract][Full Text] [Related]
16. The clinical significance of the T2-FLAIR mismatch sign in grade II and III gliomas: a population-based study.
Corell A; Ferreyra Vega S; Hoefling N; Carstam L; Smits A; Olsson Bontell T; Björkman-Burtscher IM; Carén H; Jakola AS
BMC Cancer; 2020 May; 20(1):450. PubMed ID: 32434559
[TBL] [Abstract][Full Text] [Related]
17. TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas.
Zhang ZY; Chan AK; Ding XJ; Qin ZY; Hong CS; Chen LC; Zhang X; Zhao FP; Wang Y; Wang Y; Zhou LF; Zhuang Z; Ng HK; Yan H; Yao Y; Mao Y
Oncotarget; 2015 Sep; 6(28):24871-83. PubMed ID: 26314843
[TBL] [Abstract][Full Text] [Related]
18. IDH mutation status is associated with distinct vascular gene expression signatures in lower-grade gliomas.
Zhang L; He L; Lugano R; Roodakker K; Bergqvist M; Smits A; Dimberg A
Neuro Oncol; 2018 Oct; 20(11):1505-1516. PubMed ID: 29846705
[TBL] [Abstract][Full Text] [Related]
19. Increased Radiation-Associated T-Cell Infiltration in Recurrent IDH-Mutant Glioma.
Makarevic A; Rapp C; Dettling S; Reuss D; Jungk C; Abdollahi A; von Deimling A; Unterberg A; Herold-Mende C; Warta R
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33096928
[TBL] [Abstract][Full Text] [Related]
20. Single-Cell Transcriptomics Reveals the Heterogeneity of the Immune Landscape of IDH-Wild-Type High-Grade Gliomas.
Ran X; Zheng J; Chen L; Xia Z; Wang Y; Sun C; Guo C; Lin P; Liu F; Wang C; Zhou J; Sun C; Liu Q; Ma J; Qin Z; Zhu X; Xie Q
Cancer Immunol Res; 2024 Feb; 12(2):232-246. PubMed ID: 38091354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
